Pembrolizumab-associated ocular myasthenia gravis

被引:18
作者
Liu, Qinqin [1 ]
Ayyappan, Sujith [1 ]
Broad, Adam [1 ]
Narita, Andrew [1 ]
机构
[1] Univ Hosp Geelong, Barwon Hlth, Geelong, Vic, Australia
关键词
D O I
10.1111/ceo.13499
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
引用
收藏
页码:796 / 798
页数:3
相关论文
共 4 条
[1]   CHECKPOINT INHIBITOR IMMUNE THERAPY Systemic Indications and Ophthalmic Side Effects [J].
Dalvin, Lauren A. ;
Shields, Carol L. ;
Orloff, Marlana ;
Sato, Takami ;
Shields, Jerry A. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (06) :1063-1078
[2]   Pembrolizumab [J].
Khoja, Leila ;
Butler, Marcus O. ;
Kang, S. Peter ;
Ebbinghaus, Scot ;
Joshua, Anthony M. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3
[3]   Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors [J].
Makarious, D. ;
Horwood, K. ;
Coward, J. I. G. .
EUROPEAN JOURNAL OF CANCER, 2017, 82 :128-136
[4]   Pembrolizumab-induced myasthenia gravis: A fatal case report [J].
March, Katherine L. ;
Samarin, Michael J. ;
Sodhi, Amik ;
Owens, Ryan E. .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (02) :146-149